Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2018
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PANOPTIMOX
- 05 Jun 2018 Results (n=273) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 20 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 20 Feb 2017 Status changed from recruiting to active, no longer recruiting.